Investor Presentaiton
Strong Q3 sales performance and earnings growth¹
Q3 Worldwide Sales
$16.0B
+7%
+8% ex-Exchange, ex-LAGEVRIO²
Q3 Non-GAAP EPS3,4
Full Year Sales
$59.3B
+22%
GUIDANCE RANGE
$59.7B-$60.2B
$48.7B
+17%
2021
Full Year Non-GAAP EPS3
2022
2023
$2.13
+15%
$5.37
$7.48
GUIDANCE RANGE
$1.33 - $1.38
2021
2022
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Excludes Lagevrio sales of $640 million in 3Q23 and $436 million in 3Q22. 3. Merck does not exclude expenses for upfront and milestone payments
related to collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. YTD 2023 non-GAAP results include an
aggregate $11.6 billion or $4.52 per share of R&D expenses related to the Prometheus and Imago acquisitions and upfront payment for the license and collaboration agreement with Kelun-Biotech. Full year 2022 non-GAAP
results include $690 million or $0.22 of such charges. Full year 2021 non-GAAP results include $1.7 billion or $0.65 of such charges. For 2023, guidance includes an additional $5.5 billion or $1.70 per share related to the
collaboration with Daiichi Sankyo, and guidance does not assume any additional significant potential business development transactions. 4. GAAP EPS of $1.86.
2023
MERCK
6View entire presentation